Canature Health Technology Subsidiary Enters into Letter of Intent with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Stock News03-16

Canature Health Technology Co.,Ltd. (300272.SZ) announced that its subsidiary, Shanghai Yuantian Biotechnology Co., Ltd., has signed a letter of intent for collaboration with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital. The agreement spans from 2026 to 2030, during which the subsidiary will invest a total of no less than RMB 80 million in GCP research project funding to the hospital in phases. The collaboration will focus on conducting multiple GCP and IIT research projects involving stem cell and immune cell preparations in the fields of orthopedics, ophthalmology, and aging-related diseases. The partnership aims to strengthen scientific and technological cooperation by advancing early-stage clinical research, investigator-initiated trials (IIT), drug development, and real-world studies across various disease areas. As the subsidiary's innovative drugs progress through different R&D stages and reach the market, clinical research centers or sub-centers may be established at the hospital to enhance academic influence and benefit patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112631581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112631581","market":"sg","top_or_hot":-1,"title":"Canature Health Technology Subsidiary Enters into Letter of Intent with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital","media":"Stock News","content":"<p>Canature Health Technology Co.,Ltd. (300272.SZ) announced that its subsidiary, Shanghai Yuantian Biotechnology Co., Ltd., has signed a letter of intent for collaboration with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital. The agreement spans from 2026 to 2030, during which the subsidiary will invest a total of no less than RMB 80 million in GCP research project funding to the hospital in phases. The collaboration will focus on conducting multiple GCP and IIT research projects involving stem cell and immune cell preparations in the fields of orthopedics, ophthalmology, and aging-related diseases. The partnership aims to strengthen scientific and technological cooperation by advancing early-stage clinical research, investigator-initiated trials (IIT), drug development, and real-world studies across various disease areas. As the subsidiary's innovative drugs progress through different R&D stages and reach the market, clinical research centers or sub-centers may be established at the hospital to enhance academic influence and benefit patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canature Health Technology Subsidiary Enters into Letter of Intent with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanature Health Technology Subsidiary Enters into Letter of Intent with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Canature Health Technology Co.,Ltd. (300272.SZ) announced that its subsidiary, Shanghai Yuantian Biotechnology Co., Ltd., has signed a letter of intent for collaboration with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital. The agreement spans from 2026 to 2030, during which the subsidiary will invest a total of no less than RMB 80 million in GCP research project funding to the hospital in phases. The collaboration will focus on conducting multiple GCP and IIT research projects involving stem cell and immune cell preparations in the fields of orthopedics, ophthalmology, and aging-related diseases. The partnership aims to strengthen scientific and technological cooperation by advancing early-stage clinical research, investigator-initiated trials (IIT), drug development, and real-world studies across various disease areas. As the subsidiary's innovative drugs progress through different R&D stages and reach the market, clinical research centers or sub-centers may be established at the hospital to enhance academic influence and benefit patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0224","symbol_name":"电气机械","start_time":0,"source_url":"","article_id":"1112631581","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112631581","pubTimestamp":1773648393,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Canature Health Technology Co.,Ltd. (300272.SZ) announced that its subsidiary, Shanghai Yuantian Biotechnology Co., Ltd., has signed a letter of intent for collaboration with Sichuan Academy of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300272":"开能健康","BK0224":"电气机械","BK0042":"基因检测","BK0046":"生物疫苗","BK0150":"环保概念","BK0135":"污水处理","BK0020":"浦东新区"},"translate_title":"Canature Health Technology子公司与四川省医学科学院和四川省人民医院签订意向书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300272":1},"content_text":"Canature Health Technology Co.,Ltd. (300272.SZ) announced that its subsidiary, Shanghai Yuantian Biotechnology Co., Ltd., has signed a letter of intent for collaboration with Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital. The agreement spans from 2026 to 2030, during which the subsidiary will invest a total of no less than RMB 80 million in GCP research project funding to the hospital in phases. The collaboration will focus on conducting multiple GCP and IIT research projects involving stem cell and immune cell preparations in the fields of orthopedics, ophthalmology, and aging-related diseases. The partnership aims to strengthen scientific and technological cooperation by advancing early-stage clinical research, investigator-initiated trials (IIT), drug development, and real-world studies across various disease areas. As the subsidiary's innovative drugs progress through different R&D stages and reach the market, clinical research centers or sub-centers may be established at the hospital to enhance academic influence and benefit patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112631581","isCrawlerRequest":true}